TAK1, a member of the mitogen-activated kinase kinase kinase family, is activated in vivo by various cytokines, including interleukin-1 (IL-1), or when ectopically expressed together with the TAK1-binding protein TAB1. However, this molecular mechanism of activation is not yet understood. We show here that endogenous TAK1 is constitutively associated with TAB1 and phosphorylated following IL-1 stimulation. Furthermore, TAK1 is constitutively phosphorylated when ectopically overexpressed with TAB1. In both cases, dephosphorylation of TAK1 renders it inactive, but it can be reactivated by preincubation with ATP. A mutant of TAK1 that lacks kinase activity is not phosphorylated either following IL-1 treatment or when coexpressed with TAB1, indicating that TAK1 phosphorylation is due to autophosphorylation. Furthermore, mutation to alanine of a conserved serine residue (Ser-192) in the activation loop between kinase domains VII and VIII abolishes both phosphorylation and activation of TAK1. These results suggest that IL-1 and ectopic expression of TAB1 both activate TAK1 via autophosphorylation of Ser-192.
TAK1, a member of the mitogen-activated kinase kinase kinase family, is activated in vivo by various cytokines, including interleukin-1 (IL-1), or when ectopically expressed together with the TAK1-binding protein TAB1. However, this molecular mechanism of activation is not yet understood. We show here that endogenous TAK1 is constitutively associated with TAB1 and phosphorylated following IL-1 stimulation. Furthermore, TAK1 is constitutively phosphorylated when ectopically overexpressed with TAB1. In both cases, dephosphorylation of TAK1 renders it inactive, but it can be reactivated by preincubation with ATP. A mutant of TAK1 that lacks kinase activity is not phosphorylated either following IL-1 treatment or when coexpressed with TAB1, indicating that TAK1 phosphorylation is due to autophosphorylation. Furthermore, mutation to alanine of a conserved serine residue (Ser-192) in the activation loop between kinase domains VII and VIII abolishes both phosphorylation and activation of TAK1. These results suggest that IL-1 and ectopic expression of TAB1 both activate TAK1 via autophosphorylation of Ser-192.
The mitogen-activated protein kinases (MAPKs) 1 are a family of serine/threonine kinases that have been shown to function in a wide variety of biological processes (1) (2) (3) . MAPKs are activated by phosphorylation of specific tyrosine and threonine residues by a family of dual-specificity protein kinase MAPK kinases (MAPKKs). MAPKKs are, in turn, activated by phosphorylation of serine and serine/threonine residues by MAPKK kinases (MAPKKKs) (4 -6) . Three distinct members of the MAPK family have been identified: extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38. Whereas the ERK family is activated by growth factors and is involved in cell proliferation, JNK and p38 are activated in response to proinflammatory cytokines and various types of environmental stresses. ERK family kinases are activated by the MEK1 and MEK2 MAPKKs; JNK by MKK4 and MKK7; and p38 by MKK3 and MKK6. Further upstream, Raf-1 functions as a MAPKKK in the ERK activation pathway. A subgroup of MAPKKKs including the MEKK family (MEKK1, MEKK2, MEKK3, and MEKK4/MTK1), the MLK family (MLK1, MLK2, MLK3, and DLK), ASK1, and TAK1 activate the MAPKKs that phosphorylate JNK and p38, but not the MAPKKs that phosphorylate ERK (5, 6) .
Different mechanisms activate MAPKKKs. Autophosphorylation mediated by an intramolecular reaction has been implicated in the activation of MEKK1 and Ssk2, a MAPKKK in budding yeast (7) (8) (9) . ASK1 and MLK3 have been demonstrated to form dimers in response to upstream stimuli, an event important for their catalytic activities (10, 11) . This dimerization may facilitate intermolecular autophosphorylation leading to activation, as is the case for receptor tyrosine kinases. In some signaling pathways, MAPKKKs may be activated by the action of upstream MAPKKK kinases (MAPKKKKs). For example, in the budding yeast mating pheromone pathway, MAPKKKK Ste20 functions to activate MAPKKK Ste11 (12) . Similarly, Ste20-like kinases have been implicated in the activation of MAPKKKs in mammalian cells. For example, Raf-1 is phosphorylated and activated by p21 (Rac/Cdc42)-activated kinase (13) . Germinal center kinase functions upstream of MEKK1 in the tumor necrosis factor (TNF) signaling pathway leading to JNK activation (14) ; and hematopoietic progenitor kinase and hematopoietic progenitor kinase/germinal center kinase-like kinase (HGK) are involved in the activation of TAK1 that leads to JNK activation (15, 16) .
TAK1 is a member of the MAPKKK family and is activated by various cytokines, including transforming growth factor-␤ family ligands and interleukin-1 (IL-1) (17, 18) . We have previously demonstrated that TAK1 functions in transforming growth factor-␤ signaling pathways in mammalian cells (17) . In early Xenopus embryos, TAK1 also participates in mesoderm induction and patterning meditated by bone morphogenetic protein, a transforming growth factor-␤ family ligand (19, 20) . Furthermore, we have recently demonstrated that TAK1 is involved in the IL-1 signaling pathway by activating two kinase cascades (21); one is a MAPK cascade leading to JNK activation, and the other is a kinase cascade composed of nuclear factor-B (NF-B)-inducing kinase and IB kinases, ultimately leading to NF-B activation.
TAB1 is a mammalian protein that interacts with TAK1 and was identified in a yeast two-hybrid screen (22) . When ectopically expressed together with TAK1, TAB1 can augment the kinase activity of TAK1. The C-terminal 68-amino acid portion of TAB1 is sufficient for binding to and activation of TAK1. However, the molecular mechanism for this activation remains to be elucidated.
In this report, we sought to determine the mechanism for both IL-1-and TAB1-induced activation of TAK1. We found that endogenous TAK1 associates with TAB1 constitutively and is activated by autophosphorylation following IL-1 stimulation. Similarly, ectopically expressed TAK1, once bound to TAB1, is also activated by autophosphorylation. The primary site of TAK1 autophosphorylation is Ser-192 in the kinase activation loop. Phosphorylation of this residue correlates with activation of TAK1.
EXPERIMENTAL PROCEDURES
Cell Culture and Plasmids-293 and 293IL-1RI (23) cells were maintained in Dulbecco's modified Eagle's medium supplemented with fetal calf serum (10%) at 37°C and 5% CO 2 . The mammalian expression vectors for TAB1, N-terminal hemagglutinin (HA) epitope-tagged TAK1, and TAB1 (pEF-TAB1, pEF-HA-TAK1, pEF-HA-TAK1(K63W), and pEF-HA-TAB1) have been described previously (17, 18, 22) . Several TAK1 mutants (TAK1(S192A), TAK1(S192D), and TAK1(S192E)) that contain various substitutions of a serine residue in the activation loop were generated by polymerase chain reaction. First, a 5Ј-oligonucleotide containing a SacI restriction site (TTGTGGAGCTCCGGCAGTTG) together with a 3Ј-oligonucleotide containing a NarI restriction site (TTCAGGCGCCATCCAAGCAGCAGCCCC for TAK1(S192A), TTCAG-GCGCCATCCAAGCAGCATCCCC for TAK1(S192D), or TTCAGGCGC-CATCCAAGCAGCTTCCCC for TAK1(S192E)) were used to generate TAK1 mutant fragments. The resulting DNA fragments were digested with SacI and NarI and subcloned into the SacI and NarI sites of pSP72-HA-TAK1, which contains an N-terminal HA epitope-tagged full-length TAK1 cDNA fragment in the EcoRI and BamHI sites of the vector pSP72 (Promega). The mutations were verified by DNA sequencing. Next, the EcoRI-BamHI TAK1 mutant fragments were cloned into the EcoRI and BamHI sites of the vector pEF to generate pEF-HA-TAK1 mutants. To generate the TAK1 C-terminal truncation constructs, EcoRI-PstI fragments from pEF-HA-TAK1 or pEF-HA-TAK1(K63W), containing the N-terminal HA epitope-tagged 402 amino acids of TAK1, were inserted into the EcoRI and PstI sites of the vector pKT10 (24) to add a stop codon. Then the EcoRI-SalI fragments from the above-generated pKT10-TAK1⌬C plasmids, containing the HA epitope-tagged truncated TAK1 cDNA and a stop codon, were inserted into the EcoRI and SalI sites of the pEF vector, producing pEF-HA-TAK1⌬C and pEF-HA-TAK1⌬C(K63W).
Immunoprecipitation and Immunoblotting-293IL-1RI cells were either left untreated or treated with IL-1 (10 ng/ml) for 10 min. For the transfection studies, 293 or 293IL-1RI cells (1 ϫ 10 6 ) were plated in 10-cm dishes, transfected with a total of 10 g of DNA containing various expression vectors, and incubated for 24 -36 h. Cells were washed once with phosphate-buffered saline and lysed in 0.3 ml of 0.5% Triton X-100 lysis buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM ␤-glycerophosphate, 1.5 mM MgCl 2 , 2 mM EGTA, 10 mM NaF, 2 mM dithiothreitol, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 20 M aprotinin. Cellular debris was removed by centrifugation at 10, 000 ϫ g for 5 min. Proteins from cell lysates were incubated with 1 g of anti-TAK1 antibody or anti-HA antibody HA.11 (Babco) and 15 l of protein G-Sepharose (Amersham Pharmacia Biotech). The beads were washed extensively with phosphate-buffered saline. For immunoblotting, the immunoprecipitates or whole cell lysates were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to Hybond-P membranes (Amersham Pharmacia Biotech). The membranes were immunoblotted with various antibodies, and the bound antibody was visualized with horseradish peroxidase-conjugated antibodies to rabbit or mouse IgG using the enhanced chemiluminescence Western blotting system (ECL, Amersham Pharmacia Biotech).
In Vitro Phosphorylation Assay and Phosphatase Treatment-Endogenous TAK1 or various ectopically expressed versions of HA-TAK1 were immunoprecipitated with anti-TAK1 or anti-HA antibody, respectively, as described above. Immunoprecipitates were incubated with or without 1 g of bacterially expressed MKK6 (25) in 10 l of kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl 2 , and 5 Ci of [␥- 32 P]ATP (3000 Ci/mmol) at 25°C for 2 min. Samples were fractionated by 10% SDS-PAGE and visualized by autoradiography. For phosphatase treatment, immunoprecipitates were incubated with -protein phosphatase (New England Biolabs Inc.) in phosphatase buffer containing 50 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% Brij 35, and 2 mM MnCl 2 at 30°C for 30 min. Samples were then washed twice with the lysis buffer described above and twice with phosphate-buffered saline. Some samples were further incubated with a unlabeled ATP buffer containing 20 mM Tris-HCl (pH 7.6), 20 mM MgCl 2 , 20 mM ␤-glycerophosphate, 1 mM EDTA, 1 mM sodium orthovanadate, 0.4 mM phenylmethylsulfonyl fluoride, and 1 mM ATP at 37°C for 20 min. Subsequently, samples were washed three times with phosphate-buffered saline. All samples were subjected to an in vitro phosphorylation assay as described above.
Phosphopeptide Analysis-HA-TAK1 was immunoprecipitated and phosphorylated in vitro with [␥-32 P]ATP as described above. The labeled immunoprecipitates were fractionated by SDS-PAGE and transferred to nitrocellulose membranes. The phosphorylated HA-TAK1 band was identified by autoradiography, excised, and digested with CNBr (Sigma) (26) . The resulting peptides were analyzed by Tris/ Tricine gel electrophoresis (20% polyacrylamide gels) (27) . Polypeptide SDS-PAGE standards (Bio-Rad) and a 1.0-kDa phosphopeptide generated by trypsin digestion of glutathione S-transferase-tagged IBN (IB, amino acids 1-72) phosphorylated in vitro with IB kinase (21) were used as molecular mass standards.
Reporter Gene Assay-Reporter gene activity assays were performed as described (21) . An Ig-/luciferase reporter was used to measure NF-B-dependent transcription. A plasmid containing the ␤-galactosidase gene under the control of the ␤-actin promoter was used for normalizing transfection efficiency.
RESULTS

IL-1-induced Phosphorylation of TAK1 and TAB1
Correlates with TAK1 Activity-To address how TAK1 is activated following IL-1 stimulation, we initially analyzed endogenous TAK1 complexes in untreated and IL-1-treated cells. 293 cells overexpressing the IL-1 receptor (293IL-1RI cells) were stimulated with IL-1, and cell extracts were subjected to immunoprecipitation with anti-TAK1 antibody and subsequent immunoblotting with anti-TAK1 and anti-TAB1 antibodies (Fig. 1, upper  panel) . TAK1 kinase activity was also measured in vitro using bacterially expressed MKK6 as an exogenous substrate (Fig. 1,  lower panel) . TAK1 was activated upon IL-1 treatment, as observed previously (18, 21) . Immunoblotting revealed that TAB1 coprecipitated with TAK1 in both untreated and IL-1-treated cells (Fig. 1, lanes 1 and 2) , suggesting that TAB1 constitutively associates with TAK1. However, TAK1 and TAB1 were found to migrate more slowly on SDS-PAGE when cells were treated with IL-1. Treatment with phosphatase eliminated these more slowly migrating bands, suggesting that they are the result of phosphorylation (Fig. 1, lanes 3 and 4) . Next, to test if TAK1 activity correlates with phosphorylation of TAK1 and TAB1, we examined whether dephosphorylation reduces TAK1 kinase activity. Anti-TAK1 immunoprecipitates were treated with phosphatase, extensively washed with a buffer containing phosphatase inhibitors, and measured for 293IL-1RI cells were treated (ϩ) or left untreated (Ϫ) with IL-1 (10 ng/ml) for 10 min. Cell extracts were immunoprecipitated with anti-TAK1 antibody. The immunoprecipitates were left untreated (lanes 1 and 2) or were incubated with -protein phosphatase (PPase; lanes [3] [4] [5] [6] . After phosphatase treatment, phosphatase was removed by washing the beads, and the immunoprecipitates were further incubated with ATP as described under "Experimental Procedures" (lanes 5 and 6). All samples were subjected to immunoblotting (IB) with anti-TAK1 and anti-TAB1 antibodies (upper panel) and to an in vitro phosphorylation assay using bacterially expressed MKK6 as an exogenous substrate (lower panel).
TAK1 activity in vitro. Phosphatase treatment of the TAK1 complex abolished the ability of TAK1 to phosphorylate MKK6, indicating that dephosphorylation inactivates TAK1 kinase activity (Fig. 1, lanes 3 and 4) . The phosphatase-treated immunoprecipitates were subsequently incubated with excessive amounts of unlabeled ATP and re-assayed for kinase activity. This treatment resulted in the prominent reappearance of the slowly migrating forms of TAK1 and TAB1 in both untreated and IL-1-treated cells. Concomitantly, the kinase activity of TAK1 was greatly increased (Fig. 1, lanes 5 and 6) . Thus, phosphorylation of TAK1 and TAB1 correlates with activation of TAK1. These results suggest that IL-1 activates TAK1 via phosphorylation of a preformed TAK1⅐TAB1 complex.
TAB1-induced Activation of TAK1 Correlates with Phosphorylation of TAK1-We have previously shown that TAK1 has no kinase activity when ectopically expressed alone, but is activated when TAB1 is coexpressed (18, 22) . We thus analyzed how TAB1 activates ectopically expressed TAK1. We transiently expressed HA-TAK1 alone or together with TAB1 in 293 cells. Cell extracts were subjected to immunoprecipitation with anti-HA antibody, immunoblotting, and then in vitro kinase assay (Fig. 2) . When expressed alone, HA-TAK1 appeared as a smeared band on SDS-PAGE, and coexpression with TAB1 caused a noticeable shift in its mobility. This apparent modification of TAK1 by TAB1 was accompanied by the induction of TAK1 kinase activity: activity was not detected when TAK1 was ectopically expressed alone, but was detected when TAK1 and TAB1 were coexpressed (Fig. 2, lanes 1 and 2) . These results raise the possibility that TAB1-induced activation of ectopically expressed TAK1 is mediated by phosphorylation, as is activation of endogenous TAK1 by IL-1. Treatment of the TAK1 immunoprecipitates with phosphatase both eliminated the slower migrating forms of TAK1 and abolished its kinase activity (Fig. 2, lane 4) . When immunocomplexes prepared from cells coexpressing TAK1 and TAB1 were dephosphorylated and then incubated with excessive amounts of unlabeled ATP, TAK1 was rephosphorylated, and its kinase activity was restored (Fig. 2, lane 6) . Thus, TAB1-induced activation of TAK1 correlates with phosphorylation of TAK1.
When HA-TAK1 was expressed alone in 293 cells, subjected to immunoprecipitation, dephosphorylated, and then incubated with unlabeled ATP, it was found to be neither modified nor activated (Fig. 2, lane 5) . In contrast, endogenous TAK1 was modified and activated following similar treatment, even in cells not treated with IL-1 (Fig. 1, lane 5) . The critical difference between these two cases is that endogenous TAK1 was found to be constitutively associated with TAB1, whereas most of the ectopically expressed HA-TAK1 was found unassociated. Therefore, association of TAK1 with TAB1 may be required for phosphorylation and activation of TAK1. This association is likely to be sufficient for activation of TAK1 in vitro since TAK1 is activated when TAB1 is coexpressed. On the other hand, endogenous TAK1 remains inactive even though it constitutively forms a complex with TAB1. One possibility is that overexpression of TAK1 and TAB1 somehow mimics the effect of IL-1 stimulation by overcoming the effect of some repressing factor.
As shown in Fig. 1 , phosphorylation of endogenous TAB1 correlated with TAK1 activity. Similarly, phosphorylation of ectopically expressed TAB1 also correlated with TAK1 activity (Fig. 2, lanes 2, 4, and 6) . When HA-TAK1 alone was ectopically expressed and immunoprecipitated, a small amount of endogenous TAB1 was found to coprecipitate. This associated TAB1 migrated slowly, although HA-TAK1 showed no detectable kinase activity (Fig. 2, lane 1) . One explanation for these results is that the small portion of HA-TAK1 that is bound to endogenous TAB1 is in fact catalytically active, but is too minor to be detected by our kinase assay. Consistent with this possibility, a small portion of HA-TAK1 from cells not expressing TAB1 was also observed to migrate slowly (Fig. 2, lane 1) .
IL-1 and TAB1 Induce Autophosphorylation of TAK1-IL-1-induced phosphorylation of TAK1 could be mediated by autophosphorylation or by phosphorylation in trans by another protein kinase. These two possibilities could be distinguished by testing whether a catalytically inactive mutant of TAK1 is phosphorylated upon IL-1 treatment. If another kinase is responsible for TAK1 phosphorylation, catalytically inactive TAK1 should still be phosphorylated in response to IL-1. In contrast, if autophosphorylation is responsible, catalytically inactive TAK1 would not be phosphorylated. We employed a catalytically inactive mutant of TAK1 generated by replacing a lysine in the ATP-binding site with tryptophan (HA-TAK1(K63W)). 293IL-1RI cells expressing wild-type HA-TAK1 or HA-TAK1(K63W) were left untreated or were treated with IL-1, and HA epitope-tagged proteins were immunoblotted with anti-HA antibody. Treatment with IL-1 resulted in a decrease in the mobility of HA-TAK1 (Fig. 3A, lanes 1 and 2) , similar to what was observed with endogenous TAK1 (Fig. 1) . In contrast, IL-1 stimulation had no effect on the mobility of HA-TAK1(K63W), indicating that TAK1 kinase activity is required for its phosphorylation (Fig. 3A, lanes 3 and 4) . These results suggest that TAK1 is autophosphorylated upon IL-1 treatment.
We next asked whether the TAB1-induced modification of TAK1 observed earlier is also mediated by autophosphorylation. We transiently expressed HA-TAK1(K63W) together with TAB1 in 293 cells. The HA-TAK1 and TAB1 proteins were detected with anti-HA and anti-TAB1 antibodies, respectively. No slowly migrating form of TAK1 was observed when HA-TAK1(K63W) was coexpressed with TAB1 (Fig. 3B, lanes 1 and  3) . Thus, coexpression with TAB1 stimulates TAK1 autophosphorylation activity. In addition, the slowly migrating forms of TAB1 were not observed when TAB1 was coexpressed with the kinase-inactive TAK1 derivative (Fig. 3B, lanes 1 and 3) . This suggests that phosphorylation of TAB1 is also mediated by TAK1. protein kinases, including MAPKKKs, involves the phosphorylation of serine and/or threonine residues in a region termed the kinase activation loop between subdomains VII and VIII (28) . For example, Thr-1393 of MEKK1 and Thr-1460 of budding yeast Ssk2, both located within the activation loop, are essential for their autophosphorylation and activation (7) (8) (9) . As shown in Fig. 3D , Ser-192 of TAK1 corresponds to Thr-1393 of MEKK1 and Thr-1460 of Ssk2. Therefore, we mutated this residue to alanine and tested whether the resulting mutant protein (TAK1(S192A)) was phosphorylated upon IL-1 treatment or by coexpression with TAB1. HA-TAK1(S192A) was expressed in 293IL-1RI cells, and its mobility on SDS-PAGE was examined by immunoblotting with anti-HA antibody. We found that the mobility of this mutant was unaffected by IL-1 treatment (Fig. 3A, lanes 5 and 6) or coexpression of TAB1 (Fig.  3B, lane 2) . To test if Ser-192 is essential for TAK1 kinase activity, we examined its ability to phosphorylate MKK6. In contrast to wild-type TAK1, no kinase activity was detected when the S192A mutant was coexpressed with TAB1 (Fig. 4A) . These results show that Ser-192 is important for both IL-1-and TAB1-induced autophosphorylation and activation of TAK1 and thus is probably the site for autophosphorylation.
Ser-192 in the Activation Loop of TAK1 Is Important for
To directly confirm the phosphorylation at position 192 in activated TAK1, we used high resolution Tris/Tricine gel electrophoresis to fractionate proteolyzed 32 P-labeled TAK1 (Fig.  3C ). HA-TAK1 or HA-TAK1(S192A) was coexpressed with TAB1 in 293 cells and immunoprecipitated with anti-HA antibody. The immunoprecipitates were incubated with [␥-32 P]ATP and digested with CNBr. Coexpression of TAB1 increased phosphorylation of multiple phosphopeptides of wild-type TAK1 containing a phosphopeptide of ϳ1.0 kDa (Fig. 3C, lanes 1 and   2) . Only two CNBr-cleaved fragments of TAK1 are predicted to migrate around 1.0 kDa; one is peptide 187-196, which contains Thr-187 and Ser-192, and the another is peptide 494 -502, which does not contain any serine, threonine, or tyrosine residues. Mutation of Ser-192 abolished phosphorylation of the 1.0-kDa peptide (Fig. 3C, lane 3) . Thus, we conclude that Ser-192 is a phosphorylation site of activated TAK1.
It has been shown for some kinases that replacing particular residues in the activation loop with negatively charged amino acids results in the generation of a constitutively active mutant (28) . We thus generated mutants of TAK1 in which Ser-192 was replaced with aspartic acid or glutamic acid (TAK1(S192D) or TAK1(S192E), respectively) and compared their kinase activities with that of wild-type TAK1. We found that neither mutant exhibited TAK1 kinase activity, even when coexpressed together with TAB1 ( Fig. 4A; data not shown) . These results suggest that the molecular environment achieved by phosphorylation of Ser-192 in TAK1 cannot be mimicked by replacement with negatively charged residues.
We have previously demonstrated that TAK1 activates NF-B via the NF-B-inducing kinase/IB kinase cascade (21) . To verify that phosphorylation of Ser-192 is critical for NF-B activation, we examined the effect of TAK1 mutants on activation using an NF-B-dependent reporter system (Fig. 4B) . We transiently expressed an NF-B-dependent reporter plasmid (Ig-/luciferase) together with wild-type or various mutants of TAK1. As observed previously (21), wild-type TAK1 strongly stimulated NF-B-dependent reporter expression when coexpressed with TAB1. In contrast, none of the S192A, S192D, and S192E mutants defective in kinase activity activated NF-Bdependent transcription, even when coexpressed with TAB1. Asterisks denote residues shown to be phosphorylated and implicated in the activation of these kinases.
Thus, Ser-192 is also important for TAK1-mediated activation of NF-B.
Autophosphorylation of TAK1 Is an Intramolecular Reaction-Autophosphorylation can occur by either an intra-or intermolecular reaction. To distinguish between these, we constructed an HA epitope-tagged deletion mutant of TAK1 (HA-TAK1⌬C) that lacks 176 amino acids of the TAK1 C terminus, but contains the entire kinase domain. HA-TAK1⌬C can be separated from wild-type HA-TAK1 by SDS-PAGE. We transiently expressed HA-TAK1, HA-TAK1(K63W), HA-TAK1⌬C, or the catalytically inactive mutant of HA-TAK1⌬C (HA-TAK1⌬C(K63W)) together with HA-TAB1 as an activator of TAK1. In addition, HA-TAB1 was added to monitor transphosphorylation by TAK1. Cell extracts were subjected to immunoprecipitation with anti-HA antibody followed by in vitro kinase assay. HA-TAK1, when coexpressed with HA-TAB1, became autophosphorylated and phosphorylated HA-TAB1 in trans (Fig. 5, lane 1) . HA-TAK1⌬C was catalytically active, phosphorylating both HA-TAB1 and itself (Fig. 5, lane 2) . When HA-TAK1 was coexpressed with the catalytically inactive mutant HA-TAK1⌬C(K63W) and HA-TAB1, HA-TAK1 and HA-TAB1 became phosphorylated, but HA-TAK1⌬C(K63W) did not (Fig.  5, lane 3) . Conversely, when HA-TAK1⌬C was coexpressed with the catalytically inactive mutant HA-TAK1(K63W) and TAB1, HA-TAK1⌬C and TAB1 became phosphorylated, but HA-TAK1(K63W) did not (Fig. 5, lane 4) . Thus, autophosphorylation of TAK1 is an intramolecular reaction.
DISCUSSION
The mechanisms by which MAPKKKs are activated are now being elucidated. In many cases, activation involves phosphorylation of MAPKKKs. In some signaling pathways, phosphorylation of MAPKKKs is mediated by other protein kinases such as Ste20-like MAPKKKKs. In other cases, autophosphorylation is implicated in the activation of MAPKKKs. In this study, we demonstrated that autophosphorylation of TAK1 is important for IL-1-and TAB1-induced activation of TAK1. Mutation to alanine of Ser-192, which lies in the activation loop between subdomains VII and VIII, abolishes both IL-1-and TAB1-induced phosphorylation of TAK1. Furthermore, this mutation generates a kinase-inactive form of TAK1 that is impaired in its ability to phosphorylate exogenous substrates or to activate NF-B. Based on these results, we conclude that Ser-192 is the site of TAK1 autophosphorylation and is critical for its catalytic activity. In addition, we also replaced Ser-192 with aspartic acid or glutamic acid in an attempt to mimic the negative charges resulting from phosphorylation. However, these mutations caused the loss of kinase activity. Similar observations have been reported for analogous mutants in MEK5, MKK4, and MEKK1 (8, 29) . This further suggests that the molecular environment of phosphorylated Ser-192 in TAK1 is important for its catalytic activity.
HGK, a Ste20-like MAPKKKK, has been implicated in the activation of TAK1 leading to JNK activation (16) . HGK is a serine/threonine kinase, and HGK-induced JNK activation is blocked by a kinase-negative mutant of TAK1, but not by a kinase-negative mutant of MEKK1. Since HGK is activated by TNF and UV irradiation, HGK may function as an upstream kinase for TAK1 in these signaling pathways. Given that TAK1 is activated by a variety of extracellular stimuli, including transforming growth factor-␤, TNF, IL-1, and environmental stresses (18) , it should not be surprising that TAK1 is regulated by multiple mechanisms. TNF may activate TAK1 via HGKmediated phosphorylation, whereas IL-1 activates TAK1 via autophosphorylation. Thus, it will be interesting to determine whether HGK activates TAK1 by phosphorylation of Ser-192, similar to how TAK1 is autophosphorylated in response to IL-1.
Autophosphorylation of a kinase may be mediated by either an inter-or intramolecular reaction. One common example of intermolecular autophosphorylation is the activation of receptor tyrosine kinases (30) . Upon ligand binding, these receptors form homodimers and phosphorylate their dimerized partner, resulting in activation of the kinase. Similar mechanisms of activation have been described for such MAPKKKs as ASK1 and MLK3 (10, 11) . In response to upstream stimuli, both MLK3 and ASK1 form homodimers and are consequently activated. Furthermore, they are highly active when overexpressed without upstream stimuli, presumably due to spontaneous dimerization resulting from overexpression. This is not the case for TAK1, which has virtually no kinase activity when overexpressed alone. Furthermore, we have shown here that autophosphorylation of TAK1 occurs by an intramolecular reaction. In addition, we performed co-immunoprecipitation assays using two different epitope-tagged versions of TAK1 (HA-TAK1 and FLAG-TAK1). HA-TAK1 was not coprecipitated with FLAG-TAK1 in IL-1-treated cells or in cells cotransfected with TAB1. 2 Therefore, it appears that the activation of TAK1 does not involve dimerization.
Similarly, autophosphorylation by an intramolecular reaction has been reported for MEKK1 and Ssk2 (7, 9) . The potential autophosphorylation sites of TAK1, MEKK1, and Ssk2 are present at homologous positions within their activation loops. In the case of TAK1, we have demonstrated that another protein, TAB1, is required for autophosphorylation and activation. Interestingly, autophosphorylation of Ssk2 also requires the interacting protein Ssk1, which functions as an upstream regulator of Ssk2 (9) . Thus, TAK1, Ssk2, and possibly MEKK1 may be regulated by a common activation mechanism. Collectively, these observations suggest that there are at least two different mechanisms for MAPKKK activation that involve autophosphorylation, namely dimerization-induced intermolecular autophosphorylation and regulator-dependent intramolecular autophosphorylation.
IL-1 plays a central role in proinflammatory responses. Cellular responses to IL-1 are mediated by cascades of intracellular signaling events, including activation of NF-B as well as activation of JNK (31) . Upon binding of IL-1 to its receptor, the IL-1 signal is transduced from the IL-1 receptor complex to an adapter protein, TNF-associated factor 6 (32). Following exposure of the cells to IL-1, TAK1 is recruited to the TNF-associated factor 6 complex, where it becomes activated (21). Activated TAK1 then stimulates a MAPK cascade leading to JNK activation and an NF-B-inducing kinase/IB kinase cascade leading to NF-B activation. We have demonstrated here that TAK1 is activated via autophosphorylation in response to IL-1. How, then, does IL-1 induce TAK1 autophosphorylation? Although endogenous TAK1 constitutively associates with TAB1, it remains unphosphorylated and inactive in the absence of IL-1 stimulation. Therefore, binding of TAB1 to TAK1 is not sufficient to induce phosphorylation and activation of endogenous TAK1 in vivo. On the other hand, ectopically expressed TAK1 is activated by coexpression with TAB1 even in the absence of IL-1. Furthermore, when endogenous TAK1⅐TAB1 complexes prepared from unstimulated cells are incubated in vitro with ATP, TAK1 is phosphorylated and activated. Thus, binding of TAB1 to TAK1 seems to be sufficient for activation in vitro. These results raise the possibility that a putative inhibitory factor blocks the activity of the endogenous TAK1⅐TAB1 complex in the absence of IL-1 stimulation. IL-1 treatment may disrupt this inhibitory regulation and thereby allow autophosphorylation and subsequent activation of TAK1 to proceed. Further study to identify this inhibitory regulation of TAK1 will be needed.
